• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR 0.00% 28.5¢

PARADIGM BIOPHARMACEUTICALS LIMITED..

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is engaged in researching and developing therapeutic products for human use. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PAR
Capital Raise
20:20 25 4.9K
20:20 Last post  Weazel Comments Created with Sketch.  25  Views Created with Sketch.  4.9K 
PAR
Where we at?
4 5 6
17:41 356 95K
17:41 Last post  strangelogic Comments Created with Sketch.  356  Views Created with Sketch.  95K 
PAR
Approval in Australia
04:16 1 482
04:16 Last post  Mozzarc Comments Created with Sketch.  1  Views Created with Sketch.  482 
PAR 19/04/24 45 10K
19/04/24 Last post  JamesTas Comments Created with Sketch.  45  Views Created with Sketch.  10K 
PAR
News: PAR Paradigm Biopharmaceuticals Confirms Submission To US FDA To Progress Phase 3 OA Program
19/04/24 0 149
19/04/24 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  149 
PAR
Chart
69 70 71
17/04/24 4.2K 3.7M
17/04/24 Last post  Weazel Comments Created with Sketch.  4.2K  Views Created with Sketch.  3.7M 
PAR
research reports and media
66 67 68
14/04/24 4.0K 1.8M
14/04/24 Last post  mj873 Comments Created with Sketch.  4.0K  Views Created with Sketch.  1.8M 
PAR
General OA media and info
10 11 12
08/04/24 661 243K
08/04/24 Last post  Gan_Gans Comments Created with Sketch.  661  Views Created with Sketch.  243K 

See All Discussions arrow Created with Sketch.

Timeline

Type D Response Submitted and Received by the US FDA
19 Apr 08:36
 
Notification of cessation of securities - PAR
05 Apr 19:49
 
PAR to present at NWR Healthcare Conference
20 Mar 14:45
 
Change of Director's Interest Notice
08 Mar 13:18
 
Change of Director's Interest Notice
08 Mar 13:17
 
Final Director's Interest Notice
06 Mar 09:27
 
View More arrow Created with Sketch.
(20min delay)
Last
28.5¢
Change
0.000(0.00%)
Mkt cap ! $99.83M
Open High Low Value Volume
29.0¢ 30.0¢ 28.0¢ $140.8K 481.1K

Buyers (Bids)

No. Vol. Price($)
1 1998 28.5¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 5095 1
View Market Depth
Last trade - 16.10pm 19/04/2024 (20 minute delay) ?
Last
29.0¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
29.5¢ 30.0¢ 28.0¢ 111778
Last updated 15.58pm 19/04/2024 ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.